As CEO of Interface Biologics, Tom Reeves doesn’t dwell on what might have been. For example, a few years ago, as COO of OccuLogix, he came within the blink of an eye of a billion-dollar breakthrough to treat dry age-related macular degeneration.
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today the appointment of Dr. John Denstedt, Dr. Curtis Nickel and Dr. Leonard Pinchuk to its Scientific Advisory Boar
Just about everyone on the planet will get a sliver of something in a finger at one time or another. Whether it is wood, metal, plastic or glass, if you don’t get it out, it soon becomes a painful mess of infection. Your body is just not meant to have for
À peu près tout le monde sur la planète recevra, un jour ou l’autre, un éclat de quelque chose dans le doigt. Qu’il soit de bois, de métal, de plastique ou de verre, si vous ne le retirez pas, votre doigt ne tardera pas à vous faire mal et à s’infecter. V
Implants often rely on antimicrobial coatings to prevent infections. But the release of antibacterial agents via diffusion from a biomaterial’s surface may not be the most effective approach for combating biofilm formation on implants. With this in mind,
Interface Biologics Inc. (IBI), a privately held developer of novel biomedical-polymers for use in implantable medical devices, announced today that experienced medical device executive, Arthur L. Rosenthal Ph.D., has been appointed to its Board of Direct
We are located in the MaRS Discovery District
Interface Biologics Inc. MaRS Centre, South Tower 101 College Street, Suite 300 Toronto, ON, M5G 1L7